Collaborative Study on Assays of Activated FIX (FIXa) On Behalf of the Factor VIII and Factor IX Subcommittee of the ISTH

Summary

A collaborative study has been organised by NIBSC to examine the performance of FIXa assays between laboratories, and to investigate the need for a standard. Ampoules of 3 materials, one monocomponent concentrate (coded C) and 2 different preparations of purified human FIXa (one proposed reference preparation, coded A and a test material coded B), have been assayed in 11 laboratories for FIXa using either the NIBSC method or a local method, with local standards (if available, coded D) to determine their potencies. The data showed high between assay variability; with the exception of one laboratory, most of the between assay variation expressed as %geometric coefficients of variation (gcv) were over 15%

The interlaboratory gcv when preparation B was assayed against the local standard was over 1700%, suggesting that most of the local standards are poorly calibrated. The %gcv was improved to 80% when reference A was used as the standard. These data clearly show that an international reference standard for FIXa would help to standardise FIXa preparations and would also improve in house assays for FIXa. However, an accelerated degradation study has shown that reference A is not suitable as a long term standard and another material with suitable stabilisers has to be established as an international standard for FIXa.

• References

• 1 Biousse V, Piette JC. Genetic aspects of the primary antiphospholipid syndrome. Nouv Rev Fr Hematol 1995; 37 Suppl (Suppl. 02) S65-S67
• 2 Camps MT, Cuadrado MJ, Ocon P, Alono A, Gutierrez A, Guil M, Grana MI, de Ramon E. Association between HLA class II antigens and primary antiphospholipid syndrome from the south of Spain. Lupus 1995; 4: 51-55
• 3 Asherson RA, Doherty DG, Vergani D, Khamashta MA, Hughes GRV. Major histocompatibility complex associations with primary antiphospholipid syndrome. Arthritis Rheum 1992; 35: 124-125
• 4 McNeil HP, Gavaghan TP, Krilis SA, Geczy AF, Chesterman CN. HLA-DR antigens and anticardiolipin antibodies. Clin Exp Rheum 1990; 8: 425-426
• 5 Goldstein R, Smith CD, Sengar DPS. MHC Class II studies of primary antiphospholipid antibody (APLA) syndrome and of serum antiphospholipid antibodies in systemic lupus (SLE). Arthritis Rheum 1990; 33 (suppl) SI25 (abstr)
• 6 Bentolila S, Fremeaux-Bacchi V, Weiss L, Blouift J, Kazatchkine MD, Piette JC. High prevalence of C4 “null” alleles in primary antiphospholipid syndrome. Arthritis Rheum 1995; 38 (suppl) S171 (abstr)
• 7 Working group on hemostasis of the Société Frangaise de Biologie clinique. Comparison of a standardized procedure with current laboratory practices for the detection of lupus anticoagulant in France. Thromb Haemost 1993; 70: 781-786
• 8 Cevallos R, Damiget D, Arvieux J, Veyssier P, Gruel Y. Antiphospholipid antibodies and anti-β2 glycoprotein I antibodies in monozygotic twin sisters. J Rheumatol 1994; 21: 1970-1971
• 9 Bussel J, Miller S, Hilgartner M, O’Reilly R, Kempin S, Pollack M, Miller D. Transient appearance of lupus anticoagulant in the family members sharing the A11B35DR4 haplotype. Am J Pediatr Hematol Oncol 1983; 5: 275-278
• 10 Wilson WA, Scopelitis E, Michalski J, Pierangeli SS, Silveira LH, Elston RC, Harris EG. Familial anticardiolipin antibodies and C4 deficiency genotypes that coexist with MHC DQB1 risk factors. J Rheumatol 1995; 22: 227-235